The Fertility Challenge

For women aged 35–42, fertility treatments come with greater challenges. This age group faces a higher risk of chromosomal abnormalities in embryos, which can lead to miscarriages or repeated failed IVF cycles. Despite this, current NICE guidance does not recommend routine use of genetic embryo testing, leaving many women to seek the test privately.

A new clinical trial by King’s College London, King’s College Hospital, and King’s Fertility, however, suggests that Preimplantation Genetic Testing for Aneuploidy (PGT-A) may help women in this age group conceive faster.

What Is PGT-A?

PGT-A involves testing IVF-created embryos for chromosomal abnormalities before transfer. By selecting embryos with the correct number of chromosomes, the goal is to improve the chances of implantation, reduce miscarriages, and shorten the time to a successful pregnancy.

Importantly, this study also included mosaic embryos (those with both normal and abnormal cells), which are commonly seen in IVF but rarely studied.

About the Study

• Design: Pilot randomized controlled trial (June 2021–June 2023)
• Participants: 100 women aged 35–42
  • 50 women received PGT-A
  • 50 women underwent standard embryo selection
• Conducted at: King’s Fertility

Key Findings:

• Higher live birth rate: 72% in the PGT-A group vs. 52% in the control group (after up to three embryo transfers).
• Faster time to conception: Women in the PGT-A group needed fewer transfers.
• Emotional benefit: Shorter treatment times mean less stress and physical toll.

Why This Matters

For women of advanced reproductive age, time is critical. PGT-A appears to:

• Shorten the time to conception
• Increase the chances of live birth
• Reduce the physical and emotional toll of repeated IVF cycles

This trial gives new hope for older women struggling with infertility and opens up avenues for more patient-centered fertility care.

The Road Ahead

This was a pilot study with 100 women, and while trends are promising, researchers stress the need for larger multi-centre trials. If confirmed, PGT-A could transform IVF for older women, shifting it toward a faster, more effective, and emotionally supportive journey.

Final Word

For women of advanced reproductive age, time is critical. By helping women conceive faster and with fewer failed cycles, PGT-A offers hope for more efficient fertility care.

At The Doctorpreneur Academy, we believe such innovations show how science can directly ease patients’ struggles—and why doctors must stay at the forefront of translating research into real-world care.

📖 Source & Reference

The findings, published in the Journal of Clinical Medicine, bring fresh evidence to an area of deep need.

👉To register for our next masterclass, please click here: https://linktr.ee/docpreneur